Vir Biotechnology, Inc. (NASDAQ:VIR) Receives $32.86 Average Target Price from Analysts

Shares of Vir Biotechnology, Inc. (NASDAQ:VIR - Get Free Report) have earned a consensus rating of "Moderate Buy" from the seven ratings firms that are presently covering the firm, MarketBeat Ratings reports. One equities research analyst has rated the stock with a hold recommendation and six have given a buy recommendation to the company. The average 12-month price target among brokers that have issued ratings on the stock in the last year is $32.86.

A number of equities analysts have commented on VIR shares. Needham & Company LLC reaffirmed a "buy" rating and set a $14.00 target price on shares of Vir Biotechnology in a research note on Thursday, May 22nd. The Goldman Sachs Group reduced their price target on shares of Vir Biotechnology from $28.00 to $21.00 and set a "buy" rating on the stock in a research report on Thursday, April 17th.

Insiders Place Their Bets

In other Vir Biotechnology news, Director Vicki L. Sato sold 22,000 shares of the business's stock in a transaction that occurred on Tuesday, July 1st. The shares were sold at an average price of $5.10, for a total transaction of $112,200.00. Following the completion of the transaction, the director owned 1,298,391 shares in the company, valued at $6,621,794.10. The trade was a 1.67% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. 16.00% of the stock is currently owned by company insiders.

Institutional Trading of Vir Biotechnology

Institutional investors have recently bought and sold shares of the business. SBI Securities Co. Ltd. acquired a new position in Vir Biotechnology in the fourth quarter valued at approximately $60,000. First Trust Advisors LP acquired a new position in shares of Vir Biotechnology in the 4th quarter valued at $93,000. Victory Capital Management Inc. grew its position in shares of Vir Biotechnology by 9.2% in the 4th quarter. Victory Capital Management Inc. now owns 88,776 shares of the company's stock valued at $652,000 after buying an additional 7,507 shares during the last quarter. Millennium Management LLC raised its stake in Vir Biotechnology by 55.3% during the 4th quarter. Millennium Management LLC now owns 1,715,083 shares of the company's stock worth $12,589,000 after acquiring an additional 610,367 shares in the last quarter. Finally, Price T Rowe Associates Inc. MD boosted its stake in Vir Biotechnology by 5.2% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 71,332 shares of the company's stock valued at $524,000 after acquiring an additional 3,506 shares in the last quarter. 65.32% of the stock is owned by hedge funds and other institutional investors.

Vir Biotechnology Trading Down 2.6%

Shares of NASDAQ VIR traded down $0.14 during trading on Monday, reaching $5.27. 769,779 shares of the company traded hands, compared to its average volume of 1,355,587. The stock has a market cap of $728.51 million, a P/E ratio of -1.25 and a beta of 1.22. The firm's fifty day simple moving average is $5.20 and its 200 day simple moving average is $7.08. Vir Biotechnology has a 12-month low of $4.32 and a 12-month high of $14.45.

Vir Biotechnology (NASDAQ:VIR - Get Free Report) last released its earnings results on Wednesday, May 7th. The company reported ($0.88) EPS for the quarter, missing analysts' consensus estimates of ($0.83) by ($0.05). The company had revenue of $3.03 million for the quarter, compared to analysts' expectations of $8.59 million. Vir Biotechnology had a negative return on equity of 47.46% and a negative net margin of 2,769.04%. The firm's revenue for the quarter was down 94.6% on a year-over-year basis. During the same period in the prior year, the firm earned ($0.48) EPS. As a group, research analysts expect that Vir Biotechnology will post -3.92 EPS for the current year.

About Vir Biotechnology

Vir Biotechnology, Inc, an immunology company, develops therapeutic products to treat and prevent serious infectious diseases. Its clinical development pipeline consists of product candidates targeting hepatitis delta virus (HDV), hepatitis B virus (HBV), and human immunodeficiency virus (HIV). The company's preclinical candidates include those targeting influenza A and B, coronavirus disease 2019, respiratory syncytial virus (RSV) and human metapneumovirus (MPV), and human papillomavirus (HPV).